XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection
P. P. Gerber, M. J. Donde, et al.
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms
A. M. Buck, A. N. Deitchman, et al.
Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir
G. Bolcato, M. Bissaro, et al.
Multiscale statistical physics of the pan-viral interactome unravels the systemic nature of SARS-CoV-2 infections
A. Ghavasieh, S. Bontorin, et al.
Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential
B. Meyer, J. Chiaravalli, et al.
